Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing

doi:10.1021/acs.chemrestox.8b00107

Title: Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing

Abstract

Acute myeloid leukemia (AML) is a rare yet deadly cancer of the blood and bone marrow. Presently, induction chemotherapy with the DNA damaging drugs cytarabine (ARA-C) and idarubicin (IDA), known as 7 + 3, is the standard of care for most AML patients. However, 7 + 3 is a relatively ineffective therapy, particularly in older patients, and has serious therapy-related toxicities. Therefore, a diagnostic test to predict which patients will respond to 7 + 3 is a critical unmet medical need. We hypothesize that a threshold level of therapy-induced 7 + 3 drug-DNA adducts determines cytotoxicity and clinical response. We further hypothesize that in vitro exposure of AML cells to nontoxic diagnostic microdoses enables prediction of the ability of AML cells to achieve that threshold during treatment. Our test involves dosing cells with very low levels of 14C-labeled drug followed by DNA isolation and quantification of drug-DNA adducts via accelerator mass spectrometry. Here, we have shown proof of principle by correlating ARA-C- and DOX-DNA adduct levels with cellular IC50 values of paired sensitive and resistant cancer cell lines and AML cell lines. Moreover, we have completed a pilot retrospective trial of diagnostic microdosing for 10 viably cryopreserved primary AML samplesmore »« less

Authors:

Scharadin, Tiffany M. ^[1]; Malfatti, Michael A. ^[2]; Haack, Kurt ^[2]; Turteltaub, Kenneth W. ^[2]; Pan, Chong-xian ^[3];

^[4]; Jonas, Brian A. ^[5]

Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine; Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States); VA Northern California Health Care System, Mather, CA (United States)
Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine; Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
Univ. of California, Sacramento, CA (United States). Davis School of Medicine, Division of Hematology and Oncology, Dept. of Internal Medicine; VA Northern California Health Care System, Mather, CA (United States)

Publication Date:: 2018-08-28

Research Org.:: Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)

Sponsoring Org.:: USDOE National Nuclear Security Administration (NNSA)

OSTI Identifier:: 1513119

Report Number(s):: LLNL-JRNL-769867
Journal ID: ISSN 0893-228X; 961209

Grant/Contract Number:: AC52-07NA27344

Resource Type:: Accepted Manuscript

Journal Name:: Chemical Research in Toxicology

Additional Journal Information:: Journal Volume: 31; Journal Issue: 10; Journal ID: ISSN 0893-228X

Publisher:: American Chemical Society (ACS)

Country of Publication:: United States

Language:: English

Subject:: 59 BASIC BIOLOGICAL SCIENCES

Citation Formats


                    Scharadin, Tiffany M., Malfatti, Michael A., Haack, Kurt, Turteltaub, Kenneth W., Pan, Chong-xian, Henderson, Paul T., and Jonas, Brian A. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.  United States: N. p., 2018. 
        Web.  doi:10.1021/acs.chemrestox.8b00107.

Copy to clipboard


                    Scharadin, Tiffany M., Malfatti, Michael A., Haack, Kurt, Turteltaub, Kenneth W., Pan, Chong-xian, Henderson, Paul T., & Jonas, Brian A. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing.  United States.  doi:10.1021/acs.chemrestox.8b00107.

Copy to clipboard


                    Scharadin, Tiffany M., Malfatti, Michael A., Haack, Kurt, Turteltaub, Kenneth W., Pan, Chong-xian, Henderson, Paul T., and Jonas, Brian A. Tue .  
        "Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing".  United States.  doi:10.1021/acs.chemrestox.8b00107.  https://www.osti.gov/servlets/purl/1513119.

Copy to clipboard


                    
@article{osti_1513119,

  title        = {Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing},

  author       = {Scharadin, Tiffany M. and Malfatti, Michael A. and Haack, Kurt and Turteltaub, Kenneth W. and Pan, Chong-xian and Henderson, Paul T. and Jonas, Brian A.},

  abstractNote = {Acute myeloid leukemia (AML) is a rare yet deadly cancer of the blood and bone marrow. Presently, induction chemotherapy with the DNA damaging drugs cytarabine (ARA-C) and idarubicin (IDA), known as 7 + 3, is the standard of care for most AML patients. However, 7 + 3 is a relatively ineffective therapy, particularly in older patients, and has serious therapy-related toxicities. Therefore, a diagnostic test to predict which patients will respond to 7 + 3 is a critical unmet medical need. We hypothesize that a threshold level of therapy-induced 7 + 3 drug-DNA adducts determines cytotoxicity and clinical response. We further hypothesize that in vitro exposure of AML cells to nontoxic diagnostic microdoses enables prediction of the ability of AML cells to achieve that threshold during treatment. Our test involves dosing cells with very low levels of 14C-labeled drug followed by DNA isolation and quantification of drug-DNA adducts via accelerator mass spectrometry. Here, we have shown proof of principle by correlating ARA-C- and DOX-DNA adduct levels with cellular IC50 values of paired sensitive and resistant cancer cell lines and AML cell lines. Moreover, we have completed a pilot retrospective trial of diagnostic microdosing for 10 viably cryopreserved primary AML samples and observed higher ARA-C- and DOX-DNA adducts in the 7 + 3 responders than nonresponders. In conclusion, these initial results suggest that diagnostic microdosing may be a feasible and useful test for predicting patient response to 7 + 3 induction chemotherapy, leading to improved outcomes for AML patients and reduced treatment-related morbidity and mortality.},

  doi          = {10.1021/acs.chemrestox.8b00107},

  journal      = {Chemical Research in Toxicology},

  number       = 10,

  volume       = 31,

  place        = {United States},

  year         = {2018},

  month        = {8}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (DOE)

Publisher's Version of Record

DOI: 10.1021/acs.chemrestox.8b00107

Other availability

Search WorldCat to find libraries that may hold this journal

Figures / Tables:

Table 1: Cell line IC₅₀ values with 72 h continuous treatment (μM)

All figures and tables (9 total)

Save / Share:

Export Metadata

Save to My Library

Figures / Tables found in this record:

Figures/Tables have been extracted from DOE-funded journal article accepted manuscripts.

Similar records in OSTI.GOV collections:

Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells

Journal Article Ristic, Biljana ; Bosnjak, Mihajlo ; Arsikin, Katarina ; ... - Experimental Cell Research

We investigated if the antileukemic drug idarubicin induces autophagy, a process of programmed cellular self-digestion, in leukemic cell lines and primary leukemic cells. Transmission electron microscopy and acridine orange staining demonstrated the presence of autophagic vesicles and intracellular acidification, respectively, in idarubicin-treated REH leukemic cell line. Idarubicin increased punctuation/aggregation of microtubule-associated light chain 3B (LC3B), enhanced the conversion of LC3B-I to autophagosome-associated LC3B-II in the presence of proteolysis inhibitors, and promoted the degradation of the selective autophagic target p62, thus indicating the increase in autophagic flux. Idarubicin inhibited the phosphorylation of the main autophagy repressor mammalian target of rapamycin (mTOR)more »« less
DOI: 10.1016/J.YEXCR.2014.05.021
A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer

Journal Article Wang, Si-Si ; Zimmermann, Maike ; Zhang, Hongyong ; ... - International Journal of Cancer

The platinum-based drugs cisplatin, carboplatin and oxaliplatin are often used for chemotherapy, but drug resistance is common. The prediction of resistance to these drugs via genomics is a challenging problem since hundreds of genes are involved. A possible alternative is to use mass spectrometry to determine the propensity for cells to form drug-DNA adducts—the pharmacodynamic drug-target complex for this class of drugs. In this paper, the feasibility of predictive diagnostic microdosing was assessed in non-small cell lung cancer (NSCLC) cell culture and a pilot clinical trial. Accelerator mass spectrometry (AMS) was used to quantify [ ¹⁴C]carboplatin-DNA monoadduct levels in themore »« less
Cited by 4
DOI: 10.1002/ijc.30747

Full Text Available
Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases

Journal Article Michels, S.D. ; McKenna, R.W. ; Arthur, D.C. ; ... - Blood; (United States)

This study consists of 65 patients (pts) who developed a myelodysplastic syndrome (MDS) (39 pts) or acute myeloid leukemia (AML) (26 pts) following chemotherapy and/or radiotherapy; the interval from the onset of therapy to bone marrow abnormality ranged from 11 to 192 months (median, 58). Thirty-three patients had been previously treated for lymphoproliferative diseases, 29 for carcinoma, and three for a nonneoplastic disorder. Approximately 30% of the cases presenting in the MDS phase evolved to AML in one to 12 months (median, 3.5). The AML in 49% of the cases was not readily classified according to French-American-British (FAB) criteria; themore »« less
Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel

Journal Article Wang, Sisi ; Scharadin, Tiffany M. ; Zimmermann, Maike ; ... - Chemical Research in Toxicology

Platinum drugs, including carboplatin and oxaliplatin, are commonly used chemotherapy drugs that kill cancer cells by forming toxic drug-DNA adducts. These drugs have a proven, but modest, efficacy against several aggressive subtypes of breast cancer but also cause several side effects that can lead to the cessation of treatment. There is a clinical need to identify patients who will respond to platinum drugs in order to better inform clinical decision making. Diagnostic microdosing involves dosing patients or patient samples with subtherapeutic doses of radiolabeled platinum followed by measurement of platinum-DNA adducts in blood or tumor tissue and may be usedmore »« less
Cited by 1
DOI: 10.1021/acs.chemrestox.8b00170

Full Text Available

Similar Records